Recent clinical trials26,27 of aducanumab in sporadic AD and gantenerumab in familial AD have shown that these anti-amyloid drugs reduce CSF levels of P-tau, indicating that they have downstream effects on tau metabolism. Here, MAPT is linked to amyloidosis.